Leveraging our deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, we are developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. To address a variety of infections caused by RNA viruses, we are advancing product candidates that are designed to directly inhibit viral replication by blocking the synthesis of viral RNA. Product candidate characteristics include: enhanced antiviral activity and selectivity, well tolerated profiles, convenience of once or twice daily oral administration and efficient, scaleable and reproducible manufacturing, as well as long shelf life for potential stockpiling.
A blood-borne liver infection, where a substantial unmet medical need remains for short duration and tolerable oral therapy, for large populations of patients, including those with compensated and decompensated cirrhosis, HIV co-infection, and patients at increased risk for adverse events or drug interactions with protease inhibitor-based regimens.
Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with serious viral infections. Currently, Atea is focused on the development of orally-available antiviral agents for serious viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C virus (HCV).